i-fluoropyrimidine, HER2-okuhle, i-oxaliplatin, Inkampani Seagen Inc, i-tucatinib, Tukysa
Ukugunyazwa okusheshisiwe kunikezwa yi-FDA ku-tucatinib ene-trastuzumab yomdlavuza we-colorectal
NgoFebhuwari 2023, i-Food and Drug Administration (FDA) yasheshisa ukugunyazwa kwe-tucatinib (Tukysa, Seagen Inc.) kanye ne-trastuzumab yokwelashwa kwe-RAS wild-type HER2-positive colorectal cancer osusabalele noma ongakwazi ukuphinda ulashwe.
i-fluoropyrimidine, ukuhlangana kwe-gastroesophageal (GEJ) adenocarcinoma, KEYTRUDA, I-Merck & Co, I-Pembrolizumab, I-Trastuzumab
IPembrolizumab ithola imvume esheshayo evela kwi-FDA yomdlavuza wesisu i-HER2-positive
Agasti 2021: IPembrolizumab (Keytruda, Merck & Co) ihlangene ne-trastuzumab, i-fluoropyrimidine-, ne-chemotherapy equkethe i-plotherapy inikezwe imvume esheshayo yi-Food and Drug Administration ye-firs ..
I-Bristol Myers squibb, I-CHECKMATE-649, i-fluoropyrimidine, nivolumab, I-Opdivo, I-chemotherapy equkethe i-platinum
I-Nivolumab ngaphezu kwe-chemotherapy ivunywa yi-FDA ngomdlavuza wesisu esiswini kanye ne-esophageal adenocarcinoma
Agasti 2021: Ngomdlavuza wesisu othuthukile noma we-metastatic, umdlavuza we-gastroesophageal junction, kanye ne-esophageal adenocarcinoma, iFood and Drug Administration igunyaze i-nivolumab (Opdivo, Bristol-Myers Squibb Company) ngokuhlanganyela.